TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01896531

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Participants will receive leucovorin or equivalent substitute orally, on Day 1 of each 14-day cycle (as a part of mFOLFOX6 therapy), until disease progression or unacceptable toxicity.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Leucovorin
Description: Participants will receive leucovorin or equivalent substitute orally, on Day 1 of each 14-day cycle (as a part of mFOLFOX6 therapy), until disease progression or unacceptable toxicity.
Study: NCT00713596

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fibrinogen
Description: One time application of 0.5 cc to 2.0 cc of fibrinogen following surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fibrinogen
Description: One time application of 0.5 cc to 2.0 cc of fibrinogen following surgery.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Septorhinoplasty
Description: Septorhinoplasty to correct nasal deviation.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Septorhinoplasty
Description: Septorhinoplasty to correct nasal deviation.
Study: NCT02429557

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sham abdominal compression
Description: Sham abdominal compression of 5 mmHg with a commercial inflatable cuff applied during head up tilt
Study: NCT00713596

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Septorhinoplasty
Description: Septorhinoplasty to correct nasal deviation.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Taping after septorhinoplasty.
Description: Simple taping over the nose following nasal surgery.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Taping after septorhinoplasty.
Description: Simple taping over the nose following nasal surgery.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Taping after septorhinoplasty.
Description: Simple taping over the nose following nasal surgery.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Cast applied to the nose after nasal surgery
Description: A molded cast will be placed on top of the nose following nasal surgery.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cast applied to the nose after nasal surgery
Description: A molded cast will be placed on top of the nose following nasal surgery.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Saline
Description: Approximately 0.5 cc to 2 cc normal saline will be applied after the operation before the nasal taping and casting.
Study: NCT01896531

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Participants will receive oxaliplatin via intravenous (IV) infusion on Day 1 of each 14-day cycle (part of mFOLFOX6 therapy). Oxaliplatin will be discontinued after completion of 8 cycles
Study: NCT04566861

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) for anxiety during pregnancy
Description: Women who are randomized to the intervention group will receive six core Cognitive Behavioral Therapy (CBT) sessions for anxiety during pregnancy (and possible booster sessions) to treat symptoms of anxiety.
Study: NCT02429557

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham abdominal compression
Description: Sham abdominal compression of 5 mmHg with a commercial inflatable cuff applied during head up tilt

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo pill
Description: Placebo pill given 1 hour before the second heat up tilt

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Placebo pill
Description: Placebo pill given 1 hour before the second heat up tilt
Study: NCT02967861

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pranayama
Description: Pranayama is the breathing exercise through the nostrils. It enhances the systemic immunity which in turn enhances the overall defense mechanism of an individual.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Scaling and root planing
Description: It is a mechanical debridement of dental plaque.
Study: NCT04218383

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Direct Current Stimulation
Description: Anode placed over the OFC and cathode placed over the right primary motor cortex.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial Direct Current Stimulation
Description: Anode placed over the OFC and cathode placed over the right primary motor cortex.
Study: NCT02429557

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: midodrine
Description: Midodrine single dose 2.5-10mg PO given 1 hour before the second head up tilt

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: midodrine
Description: Midodrine single dose 2.5-10mg PO given 1 hour before the second head up tilt
Study: NCT01896531

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oxaliplatin
Description: Participants will receive oxaliplatin via intravenous (IV) infusion on Day 1 of each 14-day cycle (part of mFOLFOX6 therapy). Oxaliplatin will be discontinued after completion of 8 cycles

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive matching oral placebo capsules once daily on Days 1 to 7 of each 14-day cycle until disease progression or unacceptable toxicity.
Study: NCT03932513

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: inarigivir soproxil
Description: Inarigivir 200mg and 400mg oral tablets, once daily
Study: NCT01294293

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TLR8 Agonist VTX-2337
Description: Given SC

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diagnostic Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study: NCT02855957

Intervention type: OTHER
Group type: OTHER
Intervention: Free α-Hb pool analysis
Study: NCT00639041

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: n-3 LC-PUFA
Description: n-3 LC-PUFA supplemented dairy products (yoghurt, cheese, butter): 3.3 g n-3 FA/d

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: dairy products without special oils
Study: NCT01643161

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment As Usual
Description: Communicating the diagnosis to the patient's primary care doctor and neurologist. May include referrals for physical therapy or psychiatric evaluations, or referrals to community therapists or doctors.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment As Usual
Description: Communicating the diagnosis to the patient's primary care doctor and neurologist. May include referrals for physical therapy or psychiatric evaluations, or referrals to community therapists or doctors.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Guided Self-Help
Description: A self-help workbook based on cognitive behavioral therapy, and four half-hour guidance sessions over a three-month period.
Study: NCT01404403

Intervention type: DEVICE
Group type: OTHER
Intervention: Rapid System
Study: NCT03426462

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Induction of anesthesia and two further deepening episodes will be performed whilst recording the electroencephalogram.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Induction of anesthesia and two further deepening episodes will be performed whilst recording the electroencephalogram.
Study: NCT01789060

Intervention type: OTHER
Intervention: p-AKT immunohistochemical staining
Description: p-AKT staining on the adequate paraffin-embedded biopsy specimen or unstained slides
Study: NCT01935583

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resilience/Adjustment Counseling
Description: Intervention to promote individual's resilience and adjustment (RAI) - The RAI is a structured approach to helping individuals after brain injury address issues related to resilience and adjustment. The RAI is implemented in seven sessions. Each session is in-person and lasts for 60 minutes.
Study: NCT01895543

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elobixibat 10 mg
Description: 10 mg Elobixibat daily, with possibility for dose adjustment to 5 mg daily.
Study: NCT00557310

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: teriparatide
Description: 20 mcg teriparatide subcutaneous injection per day for 18 months, with possibility to continue for 24 months
Study: NCT01713673

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ulthera System Treatment
Description: Focused ultrasound energy delivered below the surface of the skin

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Sham treatment
Description: Study treatment using the Ulthera System, but delivering no ultrasound energy.
Study: NCT03641716

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mealtime PREP Intervention
Description: Each session will include didactic elements and skills training along with skills practice and feedback. Parents will learn to build structured mealtime routines, manage child mealtime behavior, and incorporate exploration and play into routines.
Study: NCT01024972

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dantrolene
Description: Dantrolene 1.25mg/kg IV (includes 5% mannitol) every 6 hours x 7 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: equiosmolar volume (5% mannitol) every 6 hours x 7 days
Study: NCT01777217

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Solifenacin succinate
Description: IGRT with VESIcare

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IGRT with placebo
Study: NCT03650803

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3D MR Fingerprinting scan
Description: 3D MR Fingerprinting technique is a non-contrast technique and generates quantitative information about MR-visible tumors without having to administer contrast.~MR Fingerprinting software is used in conjunction with a standard-of-care MRI scan.
Study: NCT04683276

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: pars plana vitrectomy with ILM inverted flap
Description: Complete vitrectomy was done with the aid of triamcinolone acetonide followed by fluid-air exchange. Staining of the ILM was carried with 0.05% solution of Brilliant Blue dye (BBG), (Ocublue plus, Aurolab, India) for 30 seconds, ILM peeling was proceeded leaving a circle of ILM measuring approximately 1-2 DD in SF groups and \>2 to 4DD in LF group, centered around the MH. The ILM outside the parafoveal area was peeled to the arcade. The ILM around the hole was then detached from the retina up to the edge of the hole. The ILM flap around the edge of the hole was inverted over the MH using a scraper.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: pars plana vitrectomy with ILM inverted flap
Description: Complete vitrectomy was done with the aid of triamcinolone acetonide followed by fluid-air exchange. Staining of the ILM was carried with 0.05% solution of Brilliant Blue dye (BBG), (Ocublue plus, Aurolab, India) for 30 seconds, ILM peeling was proceeded leaving a circle of ILM measuring approximately 1-2 DD in SF groups and \>2 to 4DD in LF group, centered around the MH. The ILM outside the parafoveal area was peeled to the arcade. The ILM around the hole was then detached from the retina up to the edge of the hole. The ILM flap around the edge of the hole was inverted over the MH using a scraper.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: pars plana vitrectomy with ILM inverted flap
Description: Complete vitrectomy was done with the aid of triamcinolone acetonide followed by fluid-air exchange. Staining of the ILM was carried with 0.05% solution of Brilliant Blue dye (BBG), (Ocublue plus, Aurolab, India) for 30 seconds, ILM peeling was proceeded leaving a circle of ILM measuring approximately 1-2 DD in SF groups and \>2 to 4DD in LF group, centered around the MH. The ILM outside the parafoveal area was peeled to the arcade. The ILM around the hole was then detached from the retina up to the edge of the hole. The ILM flap around the edge of the hole was inverted over the MH using a scraper.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: pars plana vitrectomy with ILM inverted flap
Description: Complete vitrectomy was done with the aid of triamcinolone acetonide followed by fluid-air exchange. Staining of the ILM was carried with 0.05% solution of Brilliant Blue dye (BBG), (Ocublue plus, Aurolab, India) for 30 seconds, ILM peeling was proceeded leaving a circle of ILM measuring approximately 1-2 DD in SF groups and \>2 to 4DD in LF group, centered around the MH. The ILM outside the parafoveal area was peeled to the arcade. The ILM around the hole was then detached from the retina up to the edge of the hole. The ILM flap around the edge of the hole was inverted over the MH using a scraper.
Study: NCT03824678

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-220
Description: CC-220
Study: NCT02478697

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ProChange ExpertSystem
Description: The computer program assesses stage of change and TTM constructs of temptations, decisional balance, and processes of change. Repeat intervention contacts occur at baseline, 3- and 6-months follow-up, providing iterative computerized feedback reflecting prior responses with encouragement for quitting smoking and relapse prevention.
Study: NCT00979342

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hysteroscopic Morcellator
Description: The MyoSure Tissue Removal Device consists of a hand-held tissue removal device comprising a mechanical drive assembly connected to a drive cable and associated control box on one end, and a 3 mm shaft on the other end of the device. The shaft is approximately 12 cm long and equipped with an open channel that houses an oscillating blade.When the side channel is exposed to target tissue and the motor is activated, the oscillating blade will cut the tissue within the channel. Once cut, the tissue travels down the center of the 3mm shaft via suction coupled to the proximal end of the tissue removal device, and is trapped in a vacutainer bottle.
Study: NCT00001529

Intervention type: DRUG
Intervention: G-CSF
Study: NCT01294293

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated Liposomal Doxorubicin Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV
Study: NCT01094223

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Based Relapse Prevention
Description: Meditation based therapy group incorporating relapse prevention skills training

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Education
Description: Psychoeducation group focused on various topics pertaining to physical health
Study: NCT01171339

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Optimization strategy (complex intervention)
Description: Healthcare assistant (HCA) and computer assisted optimization of multi-medication (complex intervention) in accordance with recommended standard#~#Recommended standard: clinical practice guideline Geriatrie of the guideline group of Hesse (part 1 and 2)
Study: NCT02727023

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Osteopathic Manipulative Medicine
Description: The procedures are picked for their generalized effect on the lymphatic system based on osteopathic literature and research. Our goal is to mobilize the lymphatic fluid to induce an increase of endocannabinoids. These procedures are similar to mechanical motion seen in exercise in regards to lymphatic movement. Each technique will be performed for a total of four minutes each
Study: NCT03446469

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fascial Manipulation
Description: Myofascial release of densified centers of coordination
Study: NCT04134559

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab will be administered every 3 weeks, at predetermined dose with 21 consecutive days defined as a treatment cycle.
Study: NCT04846621

Intervention type: DRUG
Group type: OTHER
Intervention: Potassium Channel Opener
Description: Randomized Controlled comparative clinical trial between two drugs as a tocolytic agent in preterm labor

Intervention type: DRUG
Group type: OTHER
Intervention: Calcium channel blocker
Description: Randomized Controlled comparative clinical trial between two drugs as a tocolytic agent in preterm labor
Study: NCT00063973

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cilengitide
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT04068090

Intervention type: OTHER
Intervention: Patient Questionnaires
Description: FACT-Ntx, EORTC-CIPN20

Intervention type: OTHER
Intervention: Patient Questionnaires
Description: FACT-Ntx, EORTC-CIPN20

Intervention type: OTHER
Intervention: Blood Collection
Description: biomarker analysis

Intervention type: OTHER
Intervention: Blood Collection
Description: biomarker analysis
Study: NCT03582124

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Near-Infrared Fluorescence Imaging
Description: Undergo imaging

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panitumumab-IRDye800
Description: Given IV
Study: NCT02671435

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Monalizumab
Description: Participants will receive IV infusion of monalizumab as stated in arm description.
Study: NCT03582124

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacokinetic Study
Description: Correlative studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo surgery
Study: NCT03634462

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CDT with graded negative pressure
Description: Complete Decongestive Therapy (CDT)is a common conservative intervention involving stimulation of the lymphatic system, use of compression, skin care and exercise. The use of graded negative pressure in conjunction with CDT is another conservative therapy intervention used to help clear the lymphatic congestion.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CDT with graded negative pressure
Description: Complete Decongestive Therapy (CDT)is a common conservative intervention involving stimulation of the lymphatic system, use of compression, skin care and exercise. The use of graded negative pressure in conjunction with CDT is another conservative therapy intervention used to help clear the lymphatic congestion.
Study: NCT01177917

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Infant Formula

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Infant Formula
Study: NCT03970798

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: In Period 1, Day 1 a single dose will be administered after fasting for at least 10 hours. In Period 2, Day 11 a single dose will be administered after fasting for at least 10 hours.
Study: NCT02671435

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Monalizumab
Description: Participants will receive IV infusion of monalizumab as stated in arm description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Monalizumab
Description: Participants will receive IV infusion of monalizumab as stated in arm description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Monalizumab
Description: Participants will receive IV infusion of monalizumab as stated in arm description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Monalizumab
Description: Participants will receive IV infusion of monalizumab as stated in arm description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Monalizumab
Description: Participants will receive IV infusion of monalizumab as stated in arm description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Monalizumab
Description: Participants will receive IV infusion of monalizumab as stated in arm description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Monalizumab
Description: Participants will receive IV infusion of monalizumab as stated in arm description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Monalizumab
Description: Participants will receive IV infusion of monalizumab as stated in arm description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Monalizumab
Description: Participants will receive IV infusion of monalizumab as stated in arm description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Monalizumab
Description: Participants will receive IV infusion of monalizumab as stated in arm description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Monalizumab
Description: Participants will receive IV infusion of monalizumab as stated in arm description.
Study: NCT03970798

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caffeine
Description: In Period 1, Day 1 a single dose will be administered after fasting for at least 10 hours. In Period 2, Day 11 a single dose will be administered after fasting for at least 10 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: In Period 1, Day 1 a single dose will be administered after fasting for at least 10 hours. In Period 2, Day 11 a single dose will be administered after fasting for at least 10 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KW-6356
Description: In Period 2, Day 4-13(except Day11) a single dose of KW-6356 will be administered after breakfast, Day 11 a single dose of KW-6356 will be administered after fasting for at least 10 hours.
Study: NCT00211809

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Description: standard psychiatric evaluation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venlafaxine
Description: start dose of 37.5 mg/day and increased to a minimum of 150mg/day, generally over the first 4 weeks and then maintained at that dose for 8 weeks.
Study: NCT01417234

Intervention type: DEVICE
Intervention: SNaP® Wound Care System
Description: Wound dressing applications using customized system. Dressing applications changes per manufacturer recommendation.
Study: NCT02671435

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Monalizumab
Description: Participants will receive IV infusion of monalizumab as stated in arm description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Monalizumab
Description: Participants will receive IV infusion of monalizumab as stated in arm description.